Latest News

Mecasermin treatment for Rett Syndrome is safe, well-tolerated

A Phase 1 clinical trial using mecasermin [recombinant human insulin-like growth factor 1 (IGF-1)] has been completed for Rett Syndrome research, showing proof-of-principle that treatments like IGF-1 which are based on the neurobiology of Rett syndrome, are possible.
View full story

Post your comment.


  • Scientists build a digital piece of a rat's brain

  • Machines have nothing on mom when it comes to listening

  • New clues about how humans become tool users

  • Researchers learn how to grow old brain cells

  • Frequent school moves hurt low-income childrens' math scores

  • More 'global' individuals contribute less

  • Popular crime shows may help reduce sexual assault

  • 'Blind analysis' could reduce bias in social science, biology research

  • Unexpected connections: Calcium refill mechanisms in nerve cells affects gene expression

  • Preventing memory loss before symptoms appear